Clinical Trial Update: Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous DMB-3115 to Stelara in moderate to severe chronic plaque psoriasis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• DMB-3115
• Stelara (ustekinumab)

Snippet

Sponsor: Dong-A ST Co., Ltd. | Conditions: Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2024-01-18